Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of neurodegeneration and inflammatory disorders.
Shanghai Peptidstar Therapeutics Ltd. has divulged new cyclic peptides acting as interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of psoriasis, arthritis and inflammatory bowel disease.
K2 Medicines (Nanjing) Co. Ltd. has disclosed new epidermal growth factor receptor (EGFR; ERBB1; HER1) mutant inhibitors potentially useful for the treatment of cancer.
Anew Therapeutics Pte Ltd. has discovered new interleukin-17A (IL-17A)/interleukin-17 receptor A (IL-17RA) interaction inhibitors reported be useful for the treatment of Crohn’s disease, type 1 diabetes, dry eye and more.
Apolin Bio Ltd. and Shanghai Viva Dancheng Entrepreneurship Incubator Management Ltd. have detailed polycyclic compounds acting as apolipoprotein A (ApoA; LPA)/apolipoprotein B-100 (APOB) interaction inhibitors that are potentially useful for the treatment of cardiovascular disorders.
Nuvalent Inc. has described RAC-α serine/threonine-protein kinase (AKT1; PKBα) E17K mutant inhibitors reported to be useful for the treatment of cancer.
U&S Bio Co. Ltd. has divulged H+/K+-ATPase inhibitors with improved stability found to be potentially useful for the treatment of gastrointestinal disorders, cancer, Helicobacter pylori infection, sialorrhea, asthma and airways obstruction, among others.
Prelude Therapeutics Inc. has synthesized proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin-protein ligase (CRBN)-binding moiety coupled to a histone acetyltransferase KAT6A (MOZ; MYST-3)-targeting moiety that are potentially useful for the treatment of cancer.
Promomed Rus LLC has identified Janus kinase (JAK) inhibitors reported to be useful for the treatment of alopecia, atopic dermatitis, juvenile arthritis, rheumatoid arthritis, systemic lupus erythematosus and psoriatic arthritis.
RSS